Evogene Reports Negative GAAP EPS and Declining Revenue
Evogene Ltd. (NASDAQ:EVGN) reported a first-half GAAP loss per share of $0.63, with revenue falling to just $0.68 million in the period—a sharp decline from previous years due to an annual decrease of 76.4%. The company's stock dropped by nearly 9% following the earnings report. The significant drop in both profitability and top-line performance highlights ongoing challenges for Evogene, which has struggled with consistent revenue generation despite its focus on agricultural biotechnology innovation. Investors appear concerned about these results, as reflected in the sharp share price decline post-announcement.
Tickers: $EVGN
Topics: Earnings Financial Results